1.92
+0.06(+3.23%)
Currency In USD
| Previous Close | 1.86 |
| Open | 1.86 |
| Day High | 1.92 |
| Day Low | 1.83 |
| 52-Week High | 3.44 |
| 52-Week Low | 0.98 |
| Volume | 16,270 |
| Average Volume | 253,073 |
| Market Cap | 77.44M |
| PE | -10.11 |
| EPS | -0.19 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 1.89 |
| Change | 0.06 |
If you invested $1000 in BeyondSpring Inc. (BYSI) since IPO date, it would be worth $114.29 as of December 24, 2025 at a share price of $1.92. Whereas If you bought $1000 worth of BeyondSpring Inc. (BYSI) shares 5 years ago, it would be worth $173.76 as of December 24, 2025 at a share price of $1.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec.
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent sur
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker